Clinical Trial

Subthalamic Nucleus (STN)-Targeted Transcranial Temporal Interference Stimulation (TIS) for Parkinson's Disease: Efficacy and Safety From a Single-Center, Prospective, Double-Blind Randomized Controlled Trial

Study acronym: TIS-STN-PD1
Completed
View on ClinicalTrials.gov →
Summary
This is a single-center, prospective, double-blind, randomized controlled trial to evaluate the efficacy and safety of transcranial temporal interference stimulation targeting the subthalamic nucleus in patients with Parkinson's disease. It plans to enroll 20 eligible participants who will be randomly assigned in a 1:1 ratio to either the active TIS stimulation group or the sham stimulation group.
Protocol Amendment History 3 changes
critical Trial status changed: Not Yet Recruiting → Completed 2026-07-22
notable Primary completion moved earlier: 2026-12-31 -> 2026-06-20 2026-07-22
minor Completion moved earlier: 2027-06-20 -> 2026-06-20 2026-07-22
Trial Details
NCT Number NCT07361250
Lead Sponsor Tang Zhouping
Conditions Parkinson Disease
Enrollment 20 participants
Start Date 2026-01-20
Primary Completion 2026-06-20 (estimated)
Study Completion 2026-06-20 (estimated)
Updated on ClinicalTrials.gov 2026-07-21